Last reviewed · How we verify
NCT03344731: Cog
Cognitive Abilities in Brain Damaged Patients
NA trial testing Cognitive evaluation in Brain Damage in 100 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Neuromed IRCCS |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | basic science |
| Enrollment | 100 |
| Start date | 15 December 2017 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Cognitive evaluation
- Non-invasive brain stimulation
Conditions studied
- Brain Damage — all drugs for Brain Damage →
Sponsor
Neuromed IRCCS
Who can join
Adults 18 to 80, any sex, with Brain Damage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The presence of damage to the central and / or peripheral nervous system resulting from pathologies of a different nature (such as multiple sclerosis, Parkinson's disease, dementia, cranial trauma, stroke, epilepsy or other neurological syndromes) is commonly a cause of physical and mental disability. The presence of memory or language cognitive deficits is often evident at a first clinical examination. However, difficulties in cognitive areas such as decision-making, social and emotional cognition or particular forms of learning may be less evident, while exerting a strong impact on the quality of life of patients. The main purpose of this proposal is to investigate cognitive abilities in patients with neurological damage, through a series of specific tasks. In addition, the contribution of specific brain areas to the cognitive tasks will be assessed by direct modulation of brain activity. This modulation will be achieved by using non-invasive brain stimulation techniques such as Transcranial Magnetic Stimulation (TMS) and Direct Transcranial Electric Stimulation (tDCS).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03344731
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cognitive evaluation
Trials testing the same drug.
- NCT04008719 — ATtention Test and Executive Functions After STroke to Predict Depression. · NA · completed
- NCT02708927 — Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis · NA · completed
- NCT03478124 — Neuropsychological Evaluation for Early Diagnosis of PSP · completed
- NCT02391064 — Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) · NA · completed
Other recruiting trials for Brain Damage
Currently open trials in the same condition.
- NCT06027645 — Early Intervention Based on Neonatal Crawling in Very Premature Infants at Risk For Neurodevelopmental Disorder · NA · recruiting
Other Neuromed IRCCS trials
Trials by the same sponsor.
- NCT07467460 — Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disea · recruiting
- NCT06976983 — Transcranial Static Magnetic Stimulation (tSMS) in Huntington's Disease (HD) · NA · not yet recruiting
- NCT06900959 — Transcranial Static Field Stimulation (tSMS) and Transcranial Direct Current Stimulation (tDCS) for the Treatment of Neu · NA · not yet recruiting
- NCT05779449 — Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS · NA · recruiting
- NCT05784376 — The Southern Italian Children, Adolescents and PaRents COhort Study on Nutrition and Health · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03344731 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Neuromed IRCCS
- Last refreshed: 31 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03344731.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing